Stay updated with breaking news from Immune Tolerance. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Two Global Phase 2 Clinical Trials, the Phase 2 portion of ACeD-it and Phase 2a SynCeD Studies, are Ongoing in Individuals with Celiac Disease New Data Presented During Digestive Disease Week® 2024
Checking for and categorizing a suspected allergy allow physicians to draw up a management plan.
/PRNewswire/ -- The Lupus Foundation of America (LFA) is pleased to recognize two leading lupus researchers at the 2023 Evelyn V. Hess Reception. This year,...
CAMBRIDGE, Mass. & LAUSANNE, Switzerland, October 19, 2023--Anokion SA, a clinical-stage biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance, announced today that Deborah Geraghty, Ph.D., president and chief executive officer, will participate in the BofA Healthcare Trailblazers Private Company Conference on Thursday, October 26, 2023, in Boston, Mass.
Phase 2 data on the investigational drug frexalimab show favorable safety and significant reduction in new T1 brain lesions in relapsing MS.